Rituximab

Treatment Description

RItuximab is an anti-CD20 monoclonal antibody currently approved for use in B-Cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, and several autoimmune conditions.

Participating Centers

There are 103 centers running trials with this treatment. Enter a location below to find the closest center.